Latest News

Autolus Therapeutics aiming for NASDAQ IPO

This April, Autolus Therapeutics and Miltenyi Biotec inked a long-term agreement on the supply and support of Miltenyi Biotec’s CliniMACS Prodigy instruments, reagents and disposables for the manufacture of Autolus’ programmed T cell therapies. © Miltenyi Biotec


by tg

British T cell player, Autolus Therapeutics Ltd. wants to go NASDAQ selling 7.8 million American Depositary Shares (ADSs) at  at least US-$15, totaling in US$117m. Through a greenshoe option, Autolus want to offer additional 1,171,875 ADS at the IPO price. 

Goldman Sachs & Co. LLC and Jefferies LLC are acting as joint book-running managers for the offering. Wells Fargo Securities, LLC and William Blair & Company, L.L.C. are acting as lead managers.

The company is well-financed. Last September, Autolus added a US$80m Series C equity funding to US$96m raised in previous financing rounds led by Syncona Ltd., Woodford Investment Management, and Arix Bioscience plc.

Autolus‘ T cell therapies target the the blood cancer ALL either through CD19 (in Phase I) a similar approach to approved CAR-T cell therapies from Novartis and Gilead Sciences, or through targeting CD19 and CD22 (Phase I/II). The company's CD19 candidate however is claimed "next-generation" due to its fast CD19 dissociation kinetics, which allows to target many CD19+ cells very rapidly. Furthermore, the company’s CAR-T cells target CD269 and TACI to treat multiple myeloma (Phase I/II). An additional candidate undergoing Phase I safety testing targets GD2, a disialoganglioside expressed on tumours of neuroectodermal origin, to treat the rare childhood brain cancer neuroblastoma.

COVID-19: Siemens’ assay outperforms antibody tests from competitors

For Germany’s government, it is bad news: to establish immunity passports aimed at identifying people who have developed antibodies against...

Stakeholders push for further pull incentives

From August 24th to 28th, around 450 international experts discussed a whole range of topics for the global Antimicrobial Resistance (AMR) community...

Polyphor AG bags CHF19.3 in equity financing

Polyphor AG announced it has entered into an equity-linked financing arrangement with the French company IRIS to raise a gross amount of up to...

Moderna set to deliver COVID-19 jab to the EU

The EU is continuing its COVID-19 vaccine shopping spree to supply member states with enough doses to vaccinate its entire population with a...

AMR: Big Pharma sets up US$1bn Fund

Corporate members from the pharma industry associations IFPMA, PhRMA and EFPIA, vfa and BIO jointly launched the global fund on 9th July to bridge...

EC pledges €4.9bn to grant access to medicines

At the beginning of May, the European Commission (EC) had already announced funding of €4bn for COVID-19 vaccine research, €2bn for the development...

COVID-19: Lopinavir-ritonavir failed

Following unblinding of the efficacy study, the principal investigators of the RECOVERY trial concluded that there is no beneficial effect of the...